Analysis-Biotech IPOs to bloom with spotlight on startups with human trial data
By Amruta Khandekar and Bhanvi Satija (Reuters) – Initial public offerings by small private biotech companies are poised to stage a comeback later in 2023 as the pace of interest rate hikes slows, but tougher economic conditions will make investors more inclined to pick firms which have drugs in human trials. Globally, IPOs across all …
Analysis-Biotech IPOs to bloom with spotlight on startups with human trial data Read More »